Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2026 08:30 ET | Source: BioMedWire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution....
February 18, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
February 18, 2026 07:30 ET | Source: NervGen Pharma Corp.

NervGen Pharma to Participate at Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
February 12, 2026 16:15 ET | Source: NervGen Pharma Corp.

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
February 09, 2026 07:00 ET | Source: NervGen Pharma Corp.

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
January 20, 2026 07:00 ET | Source: NervGen Pharma Corp.

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

NervGen Pharma today announced that the Company will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026 in New York City
January 14, 2026 11:20 ET | Source: AstuteAnalytica India Pvt. Ltd.

Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica

Chicago, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The global central nervous system therapeutic market was valued at 129.38 billion in 2024 and is expected to reach US$ 235.87 billion by 2033, growing at a...
October 28, 2025 09:00 ET | Source: Avance Clinical

Avance Clinical Unveils Dedicated CNS Center of Excellence for Expert Clinical Trial Services in Neuroscience

Avance Clinical today announced the launch of its Center of Excellence dedicated to central nervous system (CNS) disorders.
October 15, 2025 07:05 ET | Source: SciSparc Ltd

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE...
June 30, 2025 15:15 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter...